Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say - Reuters
Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRXcwd2ZTOXFZNXBqRlU5ZERTQkVXYW1BZDFpZFpNOXVEdEk1V3pDUEdpa0FadURxcGYtMVNjRHRBSkxoWDdxcWtBcERNVUdaYkU1d1lCWlFMT1dkX3pHOVp1dnUtSko3aERhaDh5UElCd0RlcWpOQmIwNVdHbmJiUWQyZjNOQlY3QUhRWHV1N3h1QnFNdUhVemo2UkltZF9NeklhWjRmNWVuZ2ZfUEJ2Z2dmVnR3Z29N?oc=5" target="_blank">Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say</a> <font color="#6f6f6f">Reuters</font>
Dr Reddy's Laboratories plans to launch its generic semaglutide injection, potentially named Obeda, in India by March 2026, following the patent expiry of semaglutide. The company aims to price it competitively, potentially up to 60% below the branded product.
Dr Reddy's Laboratories has applied to trademark the brand name 'Obeda' for its upcoming generic version of semaglutide, the active ingredient in Novo Nordisk's Ozempic. The launch is anticipated in March 2026, coinciding with the patent expiry of semaglutide in India.
Similar Stories
Related coverage based on topic and tags
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - reuters.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide reuters.com
August 12, 2026 at 10:27 AMNovo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com
August 13, 2026 at 10:02 AMNovo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PMAs Hims prepares for peptides launch, Wall Street cautious on prospects this year - Reuters
As Hims prepares for peptides launch, Wall Street cautious on prospects this year Reuters
August 12, 2026 at 06:34 PMCapricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Reuters
August 14, 2026 at 10:41 AMUS FDA approves Regeneron's rare bone disorder drug - Reuters
US FDA approves Regeneron's rare bone disorder drug Reuters
August 19, 2026 at 06:53 PM